USANA Health Sciences (USNA)
(Delayed Data from NYSE)
$35.62 USD
-0.17 (-0.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $35.61 -0.01 (-0.03%) 5:34 PM ET
3-Hold of 5 3
A Value F Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.62 USD
-0.17 (-0.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $35.61 -0.01 (-0.03%) 5:34 PM ET
3-Hold of 5 3
A Value F Growth C Momentum B VGM
Zacks News
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
USANA Health Sciences (USNA) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -16.92% and 2.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
USNA or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 67.31% and 6.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: USANA Health Sciences (USNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USNA or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USANA Health Sciences (USNA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 27.14% and 5.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About USANA Health (USNA) Rating Upgrade to Buy
by Zacks Equity Research
USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
USANA Health Sciences (USNA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -4.76% and 0.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USANA Health Sciences (USNA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 0.88% and 0.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for USANA Health Sciences (USNA) This Earnings Season?
by Zacks Equity Research
USANA Health Sciences (USNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.